NCT05755997View on ClinicalTrials.gov

CERebrolysin In CADASIL

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cadasil
Interventions
DRUG

Cerebrolysin

40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year

DRUG

0.9 % NaCl

100 ml 0.9% NaCl per day for 4 days every month for 1 year

Trial Locations (1)

150 06

Motol University Hospital, Prague

Sponsors
All Listed Sponsors
collaborator

idv Datenanalyse & Versuchsplanung

UNKNOWN

collaborator

XClinical GmbH

INDUSTRY

lead

Ever Neuro Pharma GmbH

INDUSTRY

NCT05755997 - CERebrolysin In CADASIL | Biotech Hunter | Biotech Hunter